Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

665 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience.
De Giorgi U, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, Kozak T, Papiani G, Ballardini M, Rosti G; Solid Tumor Working Party of the European Group for Blood and Marrow Transplantation. De Giorgi U, et al. Among authors: bornhauser m. Ann Oncol. 2005 Jan;16(1):146-51. doi: 10.1093/annonc/mdi017. Ann Oncol. 2005. PMID: 15598952 Free article.
Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease.
Arnold R, Massenkeil G, Bornhäuser M, Ehninger G, Beelen DW, Fauser AA, Hegenbart U, Hertenstein B, Ho AD, Knauf W, Kolb HJ, Kolbe K, Sayer HG, Schwerdtfeger R, Wandt H, Hoelzer D. Arnold R, et al. Among authors: bornhauser m. Leukemia. 2002 Dec;16(12):2423-8. doi: 10.1038/sj.leu.2402712. Leukemia. 2002. PMID: 12454748 Clinical Trial.
Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N, Bornhäuser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG, Wandt H, Schäfer-Eckardt K, Beyer J, Kiehl M, Zander AR; German Cooperative Transplant Study Group. Kröger N, et al. Among authors: bornhauser m. Ann Hematol. 2003 Jun;82(6):336-42. doi: 10.1007/s00277-003-0654-9. Epub 2003 May 1. Ann Hematol. 2003. PMID: 12728337 Clinical Trial.
Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor.
Sayer HG, Kröger M, Beyer J, Kiehl M, Klein SA, Schaefer-Eckart K, Schwerdtfeger R, Siegert W, Runde V, Theuser C, Martin H, Schetelig J, Beelen DW, Fauser A, Kienast J, Höffken K, Ehninger G, Bornhäuser M; Cooperative German Transplant Study Group. Sayer HG, et al. Among authors: bornhauser m. Bone Marrow Transplant. 2003 Jun;31(12):1089-95. doi: 10.1038/sj.bmt.1704062. Bone Marrow Transplant. 2003. PMID: 12796788
Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.
Schetelig J, Thiede C, Bornhauser M, Schwerdtfeger R, Kiehl M, Beyer J, Sayer HG, Kroger N, Hensel M, Scheffold C, Held TK, Hoffken K, Ho AD, Kienast J, Neubauer A, Zander AR, Fauser AA, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Schetelig J, et al. Among authors: bornhauser m. J Clin Oncol. 2003 Jul 15;21(14):2747-53. doi: 10.1200/JCO.2003.12.011. J Clin Oncol. 2003. PMID: 12860954
Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation--a retrospective analysis.
Schetelig J, Bornhäuser M, Kiehl M, Schwerdtfeger R, Kröger N, Runde V, Zabelina T, Held TK, Thiede C, Fauser AA, Beelen D, Zander A, Ehninger G, Siegert W; Cooperative German Transplant Study Group. Schetelig J, et al. Among authors: bornhauser m. Bone Marrow Transplant. 2004 Mar;33(5):483-90. doi: 10.1038/sj.bmt.1704384. Bone Marrow Transplant. 2004. PMID: 14716342
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, Kobbe G, Bornhäuser M, Hochhaus A, Ullmann AJ, Kindler T, Haus U, Gschaidmeier H, Huber C, Fischer T. Hess G, et al. Among authors: bornhauser m. J Clin Oncol. 2005 Oct 20;23(30):7583-93. doi: 10.1200/JCO.2005.01.3110. J Clin Oncol. 2005. PMID: 16234522 Clinical Trial.
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Bornhäuser M, Kröger N, Schwerdtfeger R, Schafer-Eckart K, Sayer HG, Scheid C, Stelljes M, Kienast J, Mundhenk P, Fruehauf S, Kiehl MG, Wandt H, Theuser C, Ehninger G, Zander AR; Cooperative German Transplant Study Group. Bornhäuser M, et al. Eur J Haematol. 2006 Jan;76(1):9-17. doi: 10.1111/j.0902-4441.2005.t01-1-EJH2321.x. Eur J Haematol. 2006. PMID: 16343266
665 results